Skip to main content
SpringerLink
Log in

Clinically Significant Drug Interactions with Agents Specific For Migraine Attacks

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

The drugs which provide specific relief from migraine attacks, the ergopeptides (ergotamine and dihydroergotamine) and the various ‘triptans’ (notably sumatriptan), are often prescribed for persons already taking various migraine preventative agents, and sometimes drugs for other indications. As aresult, migraine-specific drugs may become involved in drug-drug interactions.

The migraine-specific drugs all act as agonists at certain subclasses of serotonin (5-hydroxytryptamine; 5-HT) receptor, particularly those of the 5-HT1D subtype, and produce vasoconstriction through these receptor-mediated mechanisms. The oral bioavailabilities of these drugs, particularly those of the ergopeptides, are often incomplete, due to extensive presystemic metabolism. As a result, if migraine-specific agents are coadministered with drugs with vasoconstrictive properties, or with drugs which inhibit the metabolism of the migraine-specific agents, there is a risk of interactions occurring which produce manifestations of excessive vasoconstriction. This can also occur through pharmacodynamic mechanisms, as when ergopeptides or triptans are coadministered with methysergide or propranolol (although a pharmacokinetic element may apply in relation to the latter interaction), or if one migraine-specific agent is used shortly after another.

When ergopeptide metabolism is inhibited by the presence of macrolide anti-bacterials, particularly troleandomycin and erythromycin, the resultant interaction can produce ergotism, sometimes leading to gangrene. Similar pharmacokinetic mechanisms, with their vasoconstrictive consequences, probably apply to combination of the ergopeptides with HIV protease inhibitors (indinavir and ritonavir), heparin, cyclosporin or tacrolimus.

Inhibition of triptan metabolism by monoamine oxidase A inhibitors, e.g. moclobemide, may raise circulating triptan concentrations, although this does not yet seem to have led to reported clinical problems.

Caffeine may cause increased plasma ergotamine concentrations through an as yet inadequately defined pharmacokinetic interaction. However, a direct anti-migraine effect of caffeine may contribute to the claimed increased efficacy of ergotamine-caffeine combinations in relieving migraine attacks.

Serotonin syndromes have been reported as probable pharmacodynamic consequences of the use of ergots or triptans in persons taking serotonin reuptake inhibitors. There have been two reports of involuntary movement disorders when sumatriptan has been used by patients already taking loxapine.

Nearly all the clinically important interactions between the ergopeptide antimigraine agents and currently marketed drugs are likely to have already come to notice. In contrast, new interactions involving the triptans are likely to be recognised as additional members of this family of drugs, with their different patterns of metabolism and pharmacokinetics, are marketed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Lance JW, Goadsby PJ. Mechanism and management of headache. 6th ed. Oxford: Butterworth-Heinemann, 1998

    Google Scholar 

  2. Peroutka SJ, Havlik S, Oksenberg D. Wolff award presentation 1993. Anti-migraine drug interactions with cloned human 5-hydroxytryptamine 1 receptor subtype. Headache 1993; 33: 347–50

    Article  PubMed  CAS  Google Scholar 

  3. Sicuteri F, Testi A, Anselmi B. Biochemical investigations in headache: increase in hydroxy-indoleacetic acid excretion during migraine attacks. Int Arch Allergy 1961; 19: 55–8

    Article  CAS  Google Scholar 

  4. Peroutka S. The pharmacology of current anti-migraine drugs. Headache 1990; 30Suppl. 1: 4–10

    Google Scholar 

  5. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache 1997; 37Suppl. 1: 15–25

    PubMed  Google Scholar 

  6. Goadsby PJ. Serotonin 5-HT1B/1D receptor agonists in migraine: comparative pharmacology and its therapeutic implications. CNS Drugs 1998; 10: 271–86

    Article  CAS  Google Scholar 

  7. Eadie MJ. Ergotamine pharmacokinetics in man: an editorial. Cephalalgia 1983; 3: 135–7

    Article  PubMed  CAS  Google Scholar 

  8. Tepper SJ, Rapoport AM. The triptans: a summary. CNS Drugs 1999; 12: 403–17

    Article  CAS  Google Scholar 

  9. Wild MJ, McKillop D, Butters CJ. Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan. Xenobiotica 1999; 29: 847–57

    Article  PubMed  CAS  Google Scholar 

  10. Milton KA, Allen MJ, Abel S, et al. The safety, tolerability, pharmacokinetics and pharmacodynamics of oral and intravenous eletriptan, a potent and selective ‘5-HT1D-like’ receptor partial agonist. Cephalalgia 1997; 17: 414–5

    Google Scholar 

  11. Delaforge M, Riviere R, Sartori E, et al. Metabolism of dihydroergotamine by a cytochrome P-450 similar to that involved in the metabolism of macrolide antibiotics. Xenobiotica 1989; 11: 1285–93

    Article  Google Scholar 

  12. Peyronneau MA, Delaforge M, Riviere R, et al. High affinity of ergopeptides for cytochromes P450 3A: importance of their peptide moiety for P450 recognition and hydroxylation of bromocriptine. Eur J Biochem 1994; 223: 947–56

    Article  PubMed  CAS  Google Scholar 

  13. Berde B, Cerletti A, Dengler HJ, et al. Studies on the interaction between ergot alkaloids and xanthine derivatives. In: Cochrane AL, editor. Background to migraine. Third Migraine Symposium 1969 Apr 24–25. London: Heinemann Medical Books, 1970: 80–102

    Google Scholar 

  14. Anderson JR, Drehsen G, Pitman IH. Effect of caffeine on ergotamine absorption from the rat small intestine. J Pharm Sci 1981; 70: 651–7

    Article  PubMed  CAS  Google Scholar 

  15. Ryan RE. Various new preparations used in the symptomatic treatment of headache. Headache 1965; 5: 18–23

    Google Scholar 

  16. Dahlof C. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993; 113: 166–71

    Article  Google Scholar 

  17. Seltzer S. Foods, and food and drug combinations, responsible for head and neck pain. Cephalalgia 1982; 2: 111–24

    Article  PubMed  CAS  Google Scholar 

  18. Lagier G, Castot A, Riboulet G, et al. A minor case of ergotism appearing to be connected with a potentiation of ergotamine tartrate by erythromycine ethyl-succinate [in French]. Therapie 1979; 34: 515–21

    PubMed  CAS  Google Scholar 

  19. Collet AM, Marcharmont D, San Marco JL, et al. Iatrogenic ergotism. Responsibility of an ergotamine tartrate-erythromycine propionate association [in French]. Semaine Hopital Paris 1982; 58: 1624–6

    CAS  Google Scholar 

  20. Francis H, Tyndall A, Webb J. Severe vascular spasm due to erythromycin-ergotamine interaction. Clin Rheumatol 1984; 3: 243–6

    Article  PubMed  CAS  Google Scholar 

  21. Ghali R, DeLean J, Douville Y, et al. Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy. Ann Vasc Surg 1993; 7: 291–6

    Article  PubMed  CAS  Google Scholar 

  22. Karam B, Farah E, Ashoush R, et al. Ergotism precipitated by erythromycin: a rare cause of vasospasm. Eur J Vasc Endovasc Surg 2000; 19: 96–8

    Article  PubMed  CAS  Google Scholar 

  23. Hayton AC. Precipitation of acute ergotism by triacetyloleandomycin. N Z Med J 1969; 69: 42

    PubMed  CAS  Google Scholar 

  24. Bigorie B, Aimez P, Soria RJ, et al. L’association triacetyl oleandomycine: tartrate d’ergotamine est-elle dangereuse? Nouv Presse Med 1975; 4: 2723–5

    PubMed  CAS  Google Scholar 

  25. Lesca H, Ossard D, Reynier P. Risk of combination of tri-acetyl-oleandomycin and ergotamine tartrate. Nouv Presse Med 1976; 5: 1832–3

    PubMed  CAS  Google Scholar 

  26. Franco A, Bourlard P, Massot C, et al. Ergotamine aigu par association dihydroergotamine-triacetyloleandomycine. Nouv Presse Med 1978; 7: 205

    PubMed  CAS  Google Scholar 

  27. Matthews NT, Havill JH. Ergotism with therapeutic doses of ergotamine tartrate. N Z Med J 1979; 89: 476–7

    PubMed  CAS  Google Scholar 

  28. Monsarrat M, Lefebvre D, Parraguette J, et al. Acute ergotism caused by an ergotamine-oleandomycin combination [in French]. Nouv Presse Med 1982; 11: 603

    PubMed  CAS  Google Scholar 

  29. Horowitz RS, Dart RC, Gommmez HE. Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction. Arch Intern Med 1996; 156: 456–8

    Article  PubMed  CAS  Google Scholar 

  30. Grolleau JY, Martin M, de la Guerrande BD, et al. Acute ergotism with a therapeutic association josamycin/ergotamine [in French]. Therapie 1981; 36: 319–21

    PubMed  CAS  Google Scholar 

  31. Boucharlat J, Franco A, Carpentier P, et al. Ergotisme en milieu psychiatrique par association D.H.E. propionate d’erythromycine. A propos d’une observation. Ann Med Psychol Paris 1980; 138: 292–6

    PubMed  CAS  Google Scholar 

  32. Neveux E, Lesgourges B, Luton JP, et al. Ergotisms aigu par association propionate d’erythromycine-dihydroergotamine. Nouv Presse Med 1981; 10: 2830

    PubMed  CAS  Google Scholar 

  33. Leroy F, Asseman P, Pruvost P, et al. Dihydroergotamine-erythromycin-induced ergotism. Ann Intern Med 1988; 109: 249

    PubMed  CAS  Google Scholar 

  34. Vayssairat M, Fiessinger JN, Bequemin MH, et al. Association dihydroergotamine et triacetyloleandomycin. Role dans une necrose digitale iatrogene. Nouv Presse Med 1978; 7: 2077

    PubMed  CAS  Google Scholar 

  35. Baudouy PY, Mellat M, Valleteau-de-Moulliac M. Myocardial infarct caused by an ergotamine tartrate-troleandomycin combination [in French]. Revue Med Intern 1988; 9: 420–2

    Article  CAS  Google Scholar 

  36. Pessayre D. Effects of macrolide antibiotics on drug metabolism in rats and in humans. Int J Clin Pharmacol Res 1983; 3: 449–58

    PubMed  CAS  Google Scholar 

  37. Sartori E, Delaforge M. Specific drug binding to rat liver cytochrome-P450 isoenzymes induced by pregnenolone-16 alpha-carbonitrile and macrolide antibiotics: implications for drug interactions. Chem Biol Interact 1990; 73: 297–307

    Article  PubMed  CAS  Google Scholar 

  38. Perrin VL. Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin Pharmacokinet 1985; 10: 334–52

    Article  PubMed  CAS  Google Scholar 

  39. Martinet M, Kiechel JR. Interaction of dihydroergotamine and triacetyloleandomycin in the minipig. Eur J Drug Metab Pharmacokinet 1983; 1983: 8

    Google Scholar 

  40. Couet W, Mathieu HP, Fourtillan JB. Effect of ponsinomycin on the pharmacokinetics of erythromycin administered orally. Fundam Clin Pharmacol 1991; 5: 47–52

    Article  PubMed  CAS  Google Scholar 

  41. Ludden TM. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985; 10: 63–79

    Article  PubMed  CAS  Google Scholar 

  42. Rosenthal E, Sala F, Chichmanian RM, et al. Ergotism related to concurrent administration of ergotamine tartrate and indinavir. J Am Med Assoc 1999; 281: 987

    Article  CAS  Google Scholar 

  43. Liaudet L, Buclin T, Jaccard C, et al. Severe ergotism associated with interaction between ritonavir and ergotamine. BMJ 1999; 318: 771

    Article  PubMed  CAS  Google Scholar 

  44. Montera A, Giovannoni AG, Tvrde PL. Leg ischemia in a patient receiving ritnovir and ergotamine. Ann Intern Med 1999; 130: 329–30

    Google Scholar 

  45. Hosea NA, Miller GP, Guengerich FP. Elucidation of distinct ligand binding sites for cytochrome P4503A4. Biochemistry 2000; 39: 5929–39

    Article  PubMed  CAS  Google Scholar 

  46. Schran HF, Bitz DW, DiSerio FJ, et al. The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. Thromb Res 1983; 31: 51–67

    Article  PubMed  CAS  Google Scholar 

  47. Rem JA, Gratzl O, Follath F, et al. Acute myocardial infarct after prophylactic administration of low doses of heparin-ergotamine: coronary artery spasm a cause? [in German]. Schweitzer Medizin Wochenschrift 1986; 116: 1814–6

    CAS  Google Scholar 

  48. Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990; 18: 595–606

    PubMed  CAS  Google Scholar 

  49. Dresser GK, Spence DJ, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P4503A4 inhibition. Clin Pharmacokinet 2000; 38: 41–57

    Article  PubMed  CAS  Google Scholar 

  50. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the smalll intestine: cytochrome P450, drug interactions and interindividual variability. Drug Metab Dispos 1995; 23: 1315–24

    PubMed  CAS  Google Scholar 

  51. Christians U, Schmidt G, Bader A, et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 1996; 41: 187–90

    Article  PubMed  CAS  Google Scholar 

  52. Fukui S, Coggia M, Goeau-Brissonniere O. Acute upper extremity ischemia during concomitant use of ergotamine tartrate and ampicillin. Ann Vasc Surg 1997; 11: 420–4

    Article  PubMed  CAS  Google Scholar 

  53. Maassen Van Der Brink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998; 98: 25–30

    Article  Google Scholar 

  54. Granier I, Garcia E, Geissler A, et al. Postpartum cerebral angiopathy associated with the administration of sumatriptan and dihydroergotamine; a case report. Intensive Care Med 1999; 25: 532–4

    Article  PubMed  CAS  Google Scholar 

  55. Henry P, d’Aliens H. Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. Headache 1993; 33: 432–5

    Article  PubMed  CAS  Google Scholar 

  56. Dixon RM, Meire HB, Evans DH, et al. Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers. Cephalalgia 1997; 17: 639–46

    Article  PubMed  CAS  Google Scholar 

  57. Kempsford RD, Nicholls B, Lam R, et al. A study to investigate the potential interaction of naratriptan and dihydroergotamine. Cephalalgia 1997; 17: 416

    Google Scholar 

  58. Kempsford RD, Nicholls B, Lam R, et al. A study to investigate the potential interaction of naratriptan and ergotamine. Cephalalgia 1997; 17: 416

    Google Scholar 

  59. Silberstein SD. Methysergide. Cephalalgia 1998; 18: 421–35

    Article  PubMed  CAS  Google Scholar 

  60. Joyce DA, Gubbay SS. Arterial complications of migraine treatment with methysergide and parenteral ergotamine. Br Med J Clin Res Ed 1982; 285: 260–1

    Article  PubMed  CAS  Google Scholar 

  61. Dagher FJ, Pais SO, Richards W, et al. Severe unilateral ischemia of the lower extremity caused by ergotamine: treatment with nifedipine. Surgery 1985; 97: 369–73

    PubMed  CAS  Google Scholar 

  62. Vaughan-Lane T. Gangrene induced by methysergide and ergotamine. A case report. J Bone Joint Surg 1979; 61: 213–4

    Google Scholar 

  63. Baumrucker JF. Drug interaction: propranolol and cafergot. N Engl J Med 1973; 288: 916

    PubMed  CAS  Google Scholar 

  64. Diamond S. Propranolol and ergotamine tartrate. N Engl J Med 1973; 289: 159

    PubMed  CAS  Google Scholar 

  65. Greenberg DJ, Hallett JWJ. Lower extremity ischemia due to combined drug therapy for migraine. 1982; 72: 103-5

  66. Gandy W. Dihydroergotamine interaction with propranolol. Ann Emerg Med 1990; 19: 221

    Article  PubMed  CAS  Google Scholar 

  67. Venter CP, Joubert PH, Buys AC. Severe peripheral ischaemia during concomitant use of beta blockers and ergot alkaloids. BMJ 1984; 289: 288–9

    Article  PubMed  CAS  Google Scholar 

  68. Matthew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia 1996; 16: 323–7

    Article  Google Scholar 

  69. Sporer KA. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf 1995; 13: 94–104

    Article  PubMed  CAS  Google Scholar 

  70. Henry PY, Larre P, Aupy M, et al. Reversible cerebral arteriopathy associated with the administration of ergot derivatives. Cephalalgia 1984; 4: 171–8

    Article  PubMed  CAS  Google Scholar 

  71. Brohult J, Forsbeerg O, Hellstrom R. A case of multiple arterial thromboses after oral contraceptives and ergotamine. Acta Med Scand 1967; 181: 453–6

    Article  PubMed  CAS  Google Scholar 

  72. O’Dell CW, Davis GB, Johnson AD, et al. Sodium nitroprusside in the treatment of ergotism. Radiology 1977; 124: 73–4

    PubMed  Google Scholar 

  73. Dierckx RA, Peters O, Ebinger G, et al. Intraarterial sodium nitroprusside infusion in the treatment of severe ergotism. Clin Neuropharmacol 1985; 9: 542–8

    Article  Google Scholar 

  74. Cobaugh DS. Prazosin treatment of ergotamine-induced peripheral ischemia. J Am Med Assoc 1980; 244: 1360

    Article  CAS  Google Scholar 

  75. Mumme A, Ernst R, Brandt A, et al. Extremity-threatening ischemia in ergotism. Successful treatment with the intra-arterial administration of nifedipine [in German]. Dtsch Med Wochenschr 1991; 116: 137–40

    Article  PubMed  CAS  Google Scholar 

  76. Horstmann R, Daum H, Heller M, et al. Critical ischemia of the extremities caused by ergotism. Treatment with intra-arterial prostaglandin E1 infusion [in German]. Dtsch Med Wochenschr 1993; 118: 1067–71

    Article  PubMed  CAS  Google Scholar 

  77. Hughes HE, Goldstein DA. Birth defects following maternal exposure to ergotamine, beta blockers, and caffeine. J Med Genet 1988; 25: 396–9

    Article  PubMed  CAS  Google Scholar 

  78. Del Rosso A, Fradella G, Russo L, et al. Pheochromocytoma crisis caused by contemporaneous ergotamine, caffeine, and nimesulide administration. Am J Med Sci 1997; 314: 396–8

    Article  PubMed  Google Scholar 

  79. Buchanan N, Cane RD, Miller M. Symmetrical gangrene of the extremities associated with the use of dopamine subsequent to ergometrine infusion. Intensive Care Med 1977; 3: 55–6

    Article  PubMed  CAS  Google Scholar 

  80. Gardner DM, Lynd LD. Sumatriptan contraindications and the serotonin syndrome. Ann Pharmacother 1998; 32: 33–8

    Article  PubMed  CAS  Google Scholar 

  81. Rolan P. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig,311 C90). Cephalalgia 1997; 17Suppl. 18: 21–7

    PubMed  Google Scholar 

  82. Van Haarst AD, Van Gerven JM, Cohen AF, et al. The effects of moclobemide on the pharmacokinetics of the 5-HT IB/1D agonist zolmitriptan in healthy volunteers. Br J Clin Pharmacol 1999; 48: 190–6

    Article  PubMed  Google Scholar 

  83. Peck RW, Seaber EJ, Dixon R, et al. The interaction between propranolol and the novel anti-migraine agent zolmitriptan (311C90). Br J Clin Pharmacol 1997; 44: 595–9

    Article  PubMed  CAS  Google Scholar 

  84. Usha Rani P, Naidu MUR, Ramesh Kumar Rao T, et al. Sumatriptan delays paracetamol absorption in migraine patients. Clin Drug Invest 1996; 11: 300–4

    Article  Google Scholar 

  85. Liston H, Bennett L, Usher BJ, et al. The association of the combination of sumatriptan and methysergide in myocardial infarction in a premenopausal woman. Arch Intern Med 1999; 159: 511–3

    Article  PubMed  CAS  Google Scholar 

  86. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997; 17: 208–21

    Article  PubMed  CAS  Google Scholar 

  87. Szabo CP. Fluoxetine and sumatriptan: possibly a counterproductive combination. J Clin Psychiatry 1995; 56: 37–8

    PubMed  CAS  Google Scholar 

  88. Joffe RT, Sokolov ST. Co-administration of fluoxetine and sumatriptan: the Canadian experience. Acta Psychiatr Scand 1997; 95: 551–2

    Article  PubMed  CAS  Google Scholar 

  89. Leung M, Ong M. Lack of an interaction between sumatriptan and selective serotonin reuptake inhibitors. Headache 1995; 35: 488–9

    Article  PubMed  CAS  Google Scholar 

  90. Scott AK. Sumatriptan. Clinical pharmacokinetics. Clin Pharmacokinet 1994; 27: 337–44

    Article  PubMed  CAS  Google Scholar 

  91. Garcia G. Dystonic reaction with sumatriptan. Ann Pharmacother 1994; 28: 1199

    PubMed  CAS  Google Scholar 

  92. Abraham JT, Brown R, Meltzer HY. Clozapine treatment of persistent paroxysmal dyskinesia associated with concomitant paroxetine and sumatriptan use. Biol Psychiatry 1997; 42: 144–6

    Article  PubMed  CAS  Google Scholar 

  93. Srinivas NR, Shyu WC, Upmalis D, et al. Lack of pharmacokinetic interaction between butorphanol tartrate nasal spray and sumatriptan succinate. J Clin Pharmacol 1995; 35: 432–7

    PubMed  CAS  Google Scholar 

  94. Van Hecken AM, Depre M, De Schepper PJ, et al. Lack of effect of flunarazine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. Br J Clin Pharmacol 1992; 34: 82–4

    Article  PubMed  Google Scholar 

  95. Scott AK, Walley T, Breckenridge AM, et al. Lack of interaction between propranolol and sumatriptan. Br J Clin Pharmacol 1991; 32: 581–4

    Article  PubMed  CAS  Google Scholar 

  96. Srinivasu P, Rambhau D, Rao RB, et al. Lack of pharmacokinetic interaction between sumatriptan and naproxen. J Clin Pharmacol 2000; 40: 99–104

    Article  PubMed  CAS  Google Scholar 

  97. Willimas P, Kempsford R, Fuseau E, et al. Absence of significant pharmacodynamic orpharmacokinetic interaction with naratriptan and sumatriptan co-administration. Cephalalgia 1997; 17: 417

    Google Scholar 

  98. Seaber E, Mohanlal R, Gillotin C, et al. Minimal interaction between 311C90, a novel antimigraine compound, and oral pizotifen. Cephalalgia 1996; 16: 395–6

    Google Scholar 

  99. Veronese L, Gillotin C, Marion-Gallois R, et al. Lack of an interaction between oral dihydroergotamine and the novel antimigraine compound zolmitriptan (‘Zomig’,3HC90) in healthy volunteers. Clin Drug Invest 1997; 14: 217–20

    Article  CAS  Google Scholar 

  100. Seaber EJ, Ridout G, Layton G, et al. The novel anti-migraine compound zolmitriptan (Zornig 311C90) has no clinically significant interactions with paracetamol or metoclopramide. Eur J Clin Pharmacol 1997; 53: 229–34

    Article  PubMed  CAS  Google Scholar 

  101. Smith DA, Cleary EW, Watkins S, et al. Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1998; 36: 301–5

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Queensland, Royal Brisbane Hospital, Ladhope Chambers, 131 Wickham Tce, Brisbane, Queensland, Australia, 4000

    Mervyn J. Eadie

Authors
  1. Mervyn J. Eadie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mervyn J. Eadie.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eadie, M.J. Clinically Significant Drug Interactions with Agents Specific For Migraine Attacks. Mol Diag Ther 15, 105–118 (2001). https://doi.org/10.2165/00023210-200115020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200115020-00003

Keywords

Search

Navigation